China's Innovation Ascendancy: Implications for Global Licensing Dynamics
Day 2 Global Pharma Outlook Stage
07/10/2026 15:45 - 16:10pm
Contributors
Meike Madelung : Engagement Manager Thought Leadership - IQVIA Commercial GmbH
China has fundamentally transformed from a low-cost manufacturing base to a global pharmaceutical innovation powerhouse. Chinese companies are now leading global biotech licensing, conducting the majority of the world's clinical trials, and developing breakthrough therapies that compete directly with Western innovation. This session examines how China's evolution from "supplier" to "innovator" is reshaping global pharmaceutical dynamics and what this means for international partnerships, competitive positioning, and investment strategies.
- China now leads global clinical trial activity with faster regulatory approval processes than traditional Western markets.
- Chinese biotech companies have shifted from licensing-in Western technologies to licensing-out their own breakthrough innovations globally.
- The domestic market has evolved from generic manufacturing to original drug discovery, creating both partnership opportunities and competitive threats.